Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The Law Offices of Frank R. Cruz reminds investors of the upcoming May 4, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) securities between July 23, 2025 and February 3, 2026, inclusive (the “Class Period”).
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Boston Scientific’s first quarter saw a strong positive market reaction, underpinned by solid organic sales growth and improved operating margins. Management...
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
